Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › SUPN
RICE HALL JAMES & ASSOCIATES, LLC position in SUPN
SUPERNUS PHARMACEUTICALS · Health Care
RICE HALL JAMES & ASSOCIATES, LLC reported holding 477,147 shares of SUPN (SUPERNUS PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$20.5M, representing 1.09% of its reported portfolio and ranking #32 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed SUPN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How RICE HALL JAMES & ASSOCIATES, LLC's SUPN position evolved
RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in SUPN in Q3 2023 at 544,468 shares (US$15.0M). The position peaked in Q1 2026 at 477,416 shares, worth US$24.7M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 4 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 477,147 shares valued at US$20.5M — a reduction of -13,074 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 544.47K | $15.01M | New |
| Q4 2023 | 529.95K | $15.34M | Reduce |
| Q1 2024 | 516.77K | $17.63M | Reduce |
| Q2 2024 | 502.59K | $13.44M | Reduce |
| Q3 2024 | 540.79K | $16.86M | Add |
| Q4 2024 | 528.35K | $19.10M | Reduce |
| Q1 2025 | 515.89K | $16.90M | Reduce |
| Q2 2025 | 524.65K | $16.54M | Add |
| Q3 2025 | 476.08K | $22.75M | Reduce |
| Q4 2025 | 467.89K | $23.25M | Reduce |
| Q1 2026 | 477.42K | $24.68M | Add |
| Q2 2026 | 490.22K | $22.80M | Add |
| Q3 2026 | 477.15K | $20.54M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SUPN and 13F data
SUPN (SUPERNUS PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in SUPN — the largest reported positions include MILLENNIUM MANAGEMENT LLC (US$179.2M), ARMISTICE CAPITAL, LLC (US$109.7M), SYSTEMATIC FINANCIAL MANAGEMENT LP (US$34.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SUPN
- MILLENNIUM MANAGEMENT LLC 3.85M sh · $179.21M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.55M sh · $109.67M · Q3 2026
- SYSTEMATIC FINANCIAL MANAGEMENT LP 804.93K sh · $34.64M · Q3 2026
- ASHFORD CAPITAL MANAGEMENT INC 616.99K sh · $26.56M · Q3 2026
- Jones Hill Capital LP 601.68K sh · $25.90M · Q3 2026
- Soleus Capital Management, L.P. 520.00K sh · $24.19M · Q2 2026
More on RICE HALL JAMES & ASSOCIATES, LLC
FAQ
How long has RICE HALL JAMES & ASSOCIATES, LLC held SUPN?
RICE HALL JAMES & ASSOCIATES, LLC has disclosed SUPN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RICE HALL JAMES & ASSOCIATES, LLC's current position in SUPN?
As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 477.15K shares of SUPN (SUPERNUS PHARMACEUTICALS), valued at $20.54M, representing 1.09% of its reported portfolio and ranking #32.
Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling SUPN?
In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC reduced its position in SUPN. The position peaked in Q1 2026 at 477.42K shares.
Which other funds hold SUPN?
Other major institutional holders of SUPN include MILLENNIUM MANAGEMENT LLC, ARMISTICE CAPITAL, LLC, SYSTEMATIC FINANCIAL MANAGEMENT LP, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.